ApconiX Press Category archive
Improve Drug Project Success by Understanding Drug Target Safety Join Professor Ruth Roberts, Director and Co-founder, ApconiX Ltd, Dr Claire Sadler, Project Toxicologist, ApconiX and Dr Leigh Ann Burns Nass, President/Owner, Magnolia Toxicology Consulting, LLC in a live webinar on Thursday, October 1, 2020 at 11am EDT (4pm BST/UK) In [...]
Dr Guy Healing Appointed Honorary Professor ApconiX is pleased to announce that Dr Guy Healing has been appointed to an Honorary Professorship in the School of Pharmacy at the University of East Anglia (UEA), Norwich, UK. Guy first became involved with the UEA when he worked for AstraZeneca. One [...]
How Alderley Park Grew into an Innovation Hub A great piece in the Financial Times this week “How Alderley Park Grew into an Innovation Hub” which highlights the success of Alderley Park following AstraZeneca’s announced departure 5 years ago. Ned Wakeman talks about his team’s continued support of the start-up companies [...]
ApconiX Welcomes Ian Slater to the Team ApconiX is delighted to welcome Ian Slater to the team. Ian has spent many years in the pharmaceutical industry as a toxicology Study Director and Study Monitor and he joins our nonclinical study monitoring team. Ian was previously an Associate Principal Toxicologist [...]
Cost Effective Study Monitoring Services at Non-Clinical CROs in North America Steve Snyder is partnering with ApconiX to provide cost-effective study monitoring services at nonclinical CROs in North America. Steve is a US-based independent consultant who currently provides study monitoring services for clients ranging from global pharmaceutical companies to [...]
Study monitoring – What is it and why is it important to drug discovery projects? Guy Healing, Senior Toxicologist at ApconiX is interviewed by Jon Clements of Metamorphic PR Pharma companies need to ensure their drugs are safe but also that they work. In drug development, this requires numerous studies to [...]
ApconiX Welcomes Steve Snyder ApconiX is delighted to welcome Steve Snyder to the team. Steve joins the nonclinical study monitoring team and is based in Florida in the United States. Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical [...]
Choosing the right non-clinical CRO Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical [...]
Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several years. Though there is a [...]
A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues [...]
